

## FORM 51 – 102F3

### MATERIAL CHANGE REPORT

**1. Name and Address of Company**

bioMmune Technologies Inc.  
1780 – 400 Burrard Street  
Vancouver, BC V6C 3A6

**2. Date of Material Change**

December 16, 2014

**3. News Release**

A news release dated December 16, 2014 was disseminated through Marketwired and was filed via SEDAR on the same day.

**4. Summary of the Material Change**

BioMmune Technologies Inc. Announces the Appointment of Expert in Biologics as New Director.

**5. Full Description of the Material Change**

VANCOUVER, BRITISH COLUMBIA, December 16th, 2014 BioMmune Technologies Inc., (TSX.V:IMU) a company focused on harnessing the body's own immune system to fight cancer and autoimmune diseases, today welcomes Professor Terry Pearson to the Board of Directors of BioMmune Technologies Inc.

Dr. Pearson is a Professor in the Department of Biochemistry and Microbiology at the University of Victoria. He obtained his PhD in Immunology under the supervision of Professors Julia Levy and Doug Kilburn from the University of British Columbia. He undertook postdoctoral work at the Medical Research Council Laboratory in Cambridge, England in the laboratory of Nobel Prize winner Sydney Brenner. While in Cambridge collaborated with Nobel Prize winner César Milstein where he was involved in the early stages of development of monoclonal antibodies and hybridoma technologies. This technology underpins most of the current biologic therapeutics used for the treatment of human diseases including cancer and autoimmune diseases such as arthritis.

For more than 35 years his research has focused on the immunology, and biochemistry of tropical diseases, mainly African sleeping sickness and on biomarkers and diagnosis of disease. Over the past decade, his research has focused on translation of basic research discoveries into application to clinical diagnostic medicine in both the developed and developing world. He is the Vice President of Research and Development and co-Founder of SISCAPA Assay Technologies, Inc., a biotechnology company that is developing transformative clinical diagnostic assays for monitoring health and disease. He is a University of Victoria Legacy award recipient for his research achievements. Dr. Pearson currently serves on the boards of several private and public biotechnology companies.

“In addition to Dr. Karoly Nikolich, Dr. Pearson will be a good addition and complement the scientific expertise of the board of bioMmune Technologies Inc.” said Dr. Reinhard Gabathuler, President of bioMmune Technologies Inc.

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

N/A

**7. Omitted Information**

N/A

**8. Executive Officer**

Dr. Reinhard Gabathuler, President  
Phone: (514) 963-6177

**9. Date of Report**

December 19, 2014